{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-26-000032","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.025209+00:00","generated_at":"2026-05-15T08:40:01.770872+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M","bullets":["Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.","FY2025 net loss $287.5M ($1.08/share); cash & equivalents $300.7M at Dec 31.","FY2026 revenue guidance $120-135M; expects shift to positive gross margin in 2026.","UK launch commenced January 2026 after NICE evaluation; ROCCA real-world data confirm safety/efficacy.","Pipeline: initial obe-cel data in progressive MS (BOBCAT) and AL amyloidosis (ALARIC) expected YE 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-26-000032","json":"https://secwatch.observer/filing/0001730463-26-000032.json","markdown":"https://secwatch.observer/filing/0001730463-26-000032.md","text":"https://secwatch.observer/filing/0001730463-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/0001730463-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/autl-20260327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:40:01.770872+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5876dc39d01fda41b7ef60104a19e7a607b04782","claim":"Autolus Therapeutics plc reported the quarter and full year ended December 31, 2025 results: revenue $23.3 million. Guidance reaffirmed.","evidence_excerpt":"Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/0001730463-26-000032-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and full year ended December 31, 2025"},{"label":"Revenue","value":"$23.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}